Related Experiment Video
Updated: Jul 6, 2026
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Antithrombotic and thrombolytic therapy for ischemic stroke
Oriana Cornett1, Lenore C Ocava, Manjeet Singh
1Department of Neurology, SUNY Downstate, 450 Clarkson Avenue, Brooklyn, NY 11203, USA.
Cardiology Clinics
|April 15, 2008
Summary
Recombinant tissue plasminogen activator (rt-PA) is key for acute stroke treatment, while antiplatelet drugs and anticoagulation prevent recurrence. Research aims to expand treatment windows and improve safety profiles for stroke patients.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Thrombolytic and antithrombotic agents are crucial for stroke management.
- Recombinant tissue plasminogen activator (rt-PA) improves outcomes when given within 3 hours of stroke onset.
- Bleeding risk associated with rt-PA is a concern, though not elevated in geriatric patients.
Purpose of the Study:
- To review current thrombolytic and antithrombotic therapies for stroke.
- To discuss emerging strategies for extending the therapeutic window for rt-PA.
- To evaluate antiplatelet and anticoagulant therapies for stroke prevention.
Main Methods:
- Review of large randomized trials and clinical studies.
- Analysis of risk-benefit ratios for different therapeutic agents.
- Evaluation of safety profiles and effectiveness in stroke treatment and prevention.
Main Results:
- Early and continuous antiplatelet therapy effectively reduces atherothrombotic stroke recurrence.
- Aspirin is the standard, but other agents show greater efficacy.
- Oral anticoagulation is recommended for preventing cardioembolic stroke.
Conclusions:
- Optimizing rt-PA use and exploring new agents are critical for acute stroke care.
- Effective antiplatelet and anticoagulant strategies are vital for secondary stroke prevention.
- Ongoing research focuses on improving safety and efficacy in stroke management.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...